Drug intelligence / Profile preview

AdiaVita

Development stage: Phase 1
Lead developer: ADIA Nutrition
Modality: Stem Cell Therapies → Cell Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

AdiaVita is an investigational regenerative biologic product developed by Adia Med. It is described in registered clinical studies as a preparation of umbilical cord blood-derived stem cells and exosomes, administered intravenously. The product is being evaluated alone or alongside glutathione in early-stage studies for autism spectrum disorder, chronic kidney disease, and chronic mechanical lower back pain. Its precise cellular composition, exosome characterization, potency assay, and target-specific mechanism of action have not been publicly established. AdiaVita is not an approved therapy.

Brand names: AdiaVitaAdia Vita
Other names: umbilical cord blood-derived stem cells and exosomesumbilical cord blood plasma combined with mononuclear cellsUCB-PM

Beyond the preview

Go deeper on AdiaVita.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AdiaVita.